APM News and Press, Aptorum Group Limited From 12/16/22

APM - Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced t...

APM - Aptorum Group dips on offering of $3M convertible note due 2023

Aptorum Group ( NASDAQ: APM ) announced a private offering of $3M aggregate principal amount of convertible note due 2023. The note will be solely subscribed by Aenco Technologies which is indirectly 34.56% effectively owned by Mr. Ian Huen, a Non-Executive Director and major...

APM - Aptorum Group Announces Offering of $3 Million Convertible Note due 2023

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced a...

APM - Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce the recent publication of a joint effort fo...

APM - Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today a...

APM - Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today a...

APM - Aptorum Group GAAP EPS of -$0.05

Aptorum Group press release ( NASDAQ: APM ): 1H GAAP EPS of -$0.05. As of June 30, 2022, cash and restricted cash totalled approximately $7.2 million and total equity was approximately $15.6 million. Aptorum Group expects that its existing cash and restricted cash toge...

APM - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provid...

APM - Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to tackling unmet medical needs, announces the commercial launch of NativusWell &#...

APM - Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune diseases and infectious diseases, is pleased to announce further updates on the analytical and both ...

Company Name:	Aptorum Group Limited
Stock Symbol:	APM
Market:	NASDAQ
Website:	aptorumgroup.com